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ABSTRACT
Purpose of our study was to explore a new immunotherapy for high grade soft tissue sarcomas (STS) based
on cytokine-induced killer cells (CIK) redirected with a chimeric antigen receptor (CAR) against the tumor-
promoting antigen CD44v6. We aimed at generating bipotential killers, combining the CAR specificity with
the intrinsic tumor-killing ability of CIK cells (CARC.CIK). We set a patient-derived experimental platform.
CARC.CIK were generated by transduction of CIK precursors with a lentiviral vector encoding for anti-
CD44v6-CAR. CARC.CIK were characterized and assessed in vitro against multiple histotypes of patient-
derived STS. The anti-sarcoma activity of CARC.CIK was confirmed in a STS xenograft model. CD44v6 was
expressed by 40% (11/27) of patient-derived STS. CARC.CIK were efficiently expanded from patients
(n D 12) and killed multiple histotypes of STS (including autologous targets, n D 4). The killing activity was
significantly higher compared with unmodified CIK, especially at low effector/target (E/T) ratios: 98% vs
82% (E/T D 10:1) and 68% vs 26% (1:4), (p<0.0001). Specificity of tumor killing was confirmed by blocking
with anti-CD44v6 antibody. CARC.CIK produced higher amounts of IL6 and IFN-g compared to control CIK.
CARC.CIK were highly active in mice bearing subcutaneous STS xenografts, with significant delay of tumor
growth (p<0.0001) without toxicities.
We report first evidence of CARC.CIK’s activity against high grade STS and propose CD44v6 as an
innovative target in this setting. CIK are a valuable platform for the translation of CAR-based strategies to
challenging field of solid tumors. Our findings support the exploration of CARC.CIK in clinical trials against
high grade STS.
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Introduction
In this study, we explored the anti-sarcoma activity of a new
adoptive immunotherapy strategy, based on Cytokine-Induced
Killer cells (CIK) redirected with a Chimeric Antigen Receptor
(CAR) against the isoform variant 6 of adhesive receptor CD44
(CD44v6). 1-3Soft tissue sarcomas (STS) are a heterogeneous
group of mesenchymal tumors and, in advanced stages, repre-
sent a highly unmet medical need. Conventional treatments
usually fail to cure advanced STS patients, in most cases young
adults, and there is an urgent need for new therapeutic
approaches.4 Adoptive immunotherapy is among the most
promising strategies for treatment of chemo-refractory solid
tumors.5 T lymphocytes redirected with a clonal T cell receptor
(TCR) anti-NY-ESO1 have demonstrated significant clinical
responses, including remissions, in selected cases of synovial
sarcomas.6,7 These findings constitute an important proof-of-
concept on the potential efficacy of adoptive immunotherapy
in sarcomas and brought new hopes and enthusiasm in the
field. This first example is however restricted to the few selected
cases that express the NY-ESO1 target antigen and is only
applicable to patients with a precise HLA haplotype (e.g.
HLA-A2). The exploration and development of alternative
immunotherapy strategies, with a wider spectrum of applicabil-
ity, are still needed for the majority of STS patients.
To this purpose, immunotherapy with CIK appears a prom-
ising option.
CIK are ex vivo expanded T lymphocytes, endowed with
T-NK phenotype and intense MHC-independent antitumor
ability reported against various types of solid and hemato-
logic malignancies.8-13 Recent clinical trials support their
activity and an excellent safety profile in challenging set-
tings such as lung, renal, liver, breast and gastrointestinal
cancers.14-16 A summary of the main clinical findings was
also published in the International Registry on CIK Cells
(IRCC).17 Overall, a beneficial effect of CIK emerged in
patients with hepatocellular carcinoma, renal cell carcinoma,
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non-small cell lung cancer (NSCLC), colorectal carcinoma,
and breast cancer.17
The intrinsic tumor killing ability of CIK is mainly mediated
by the NKG2D receptor that recognizes, in MHC-independent
manner, stress-inducible targets (MIC A/B, ULBPs) which are
selectively expressed by transformed cells.18,19 The subset of
CIK co-expressing CD3 and CD56 molecules (CD3CCD56C) is
present at variable rates and is considered the most capable of
antitumor activity. CIK with CD3CCD56¡ phenotype have a
minor, but however positive, tumor-killing capacity.20
Importantly, NKG2D ligands are not restricted to a specific
tumor histotype since their expression has been described in
various epithelial cancers and we recently confirmed this find-
ing in various types of sarcomas.11
We reported that patient-derived CIK are active against autolo-
gous STS, but observed that their function decreases at low effec-
tor/target (E/T) ratios, thus showing limitations in clinical
perspective.
Adoptive immunotherapy with CIK might greatly benefit
from the new redirection opportunities offered by the developing
strategies with engineered tumor-specific receptors.6,7,21,22 In par-
ticular, CAR-based approaches showed impressive therapeutic
potential in selected hematologic malignancies even if with rele-
vant safety warnings.23 CARs are constructed by fusing the single
chain variable fragment (scFv) of a tumor surface antigen-spe-
cific monoclonal antibody with an intracellular TCR-derived sig-
naling domain and costimulatory molecules.24,25
Most importantly, their clinical application is not restricted
by HLA-haplotypes with the important implication that, if a
meaningful tumor antigen is identified, this strategy may be in
theory appropriate to all patients affected by tumors expressing
that specific target. The effective translation of CAR-strategies
to the field of solid tumors has been so far disappointing and it
is still object of intense research.22
The first evaluation of a CAR strategy in sarcoma patients,
with anti-HER2-CAR T cells, provided initial proof of concept
about its feasibility and limited evidence of activity.26
CIK with their biologic features might provide an intriguing
platform for CAR-strategies, with potential positive impact in the
challenging translation to the field of solid tumors and favorable
safety implications. CAR engineered CIK would generate bi-spe-
cific tumor killers, conjugating in the same effector the CAR-
specificity with the intrinsic NKG2D-mediated antitumor capac-
ity. Advantages may derive by enhanced efficacy against tumors
with heterogeneous antigen expression and by the possible con-
trast to tumor clonal selection events. CIK have demonstrated a
very favorable safety profile in the early clinical trials.9,27-29 Their
limited lifespan and persistence in vivo requires multiple thera-
peutic infusions but might acquire a positive valence in terms of
safety when considering CAR-CIK.30
Initial feasibility of CAR engineering and preclinical activity
of CAR-CIK were reported against selected hematologic malig-
nancies,31-34 boosting recent scientific interest and need for
their investigation in solid tumor settings.35,36
A crucial issue in CAR strategies is the identification of a suit-
able target antigen. Ideally it should be selectively expressed by
tumor cells and sustaining their growth. The CD44v6 may be an
ideal target for immunotherapy as it is a tumor-promoting antigen,
associated with the metastatic process and tumor initiating cells.2,37
CD44v6 is broadly expressed in hematologicmalignancies and sev-
eral solid tumors.38 Few retrospective studies described CD44v6
expression in selected STS, reporting a possible correlation with the
clinical aggressiveness and patients’ prognosis.1,39
The significant preclinical antitumor efficacy of anti-
CD44v6 CAR-T cells against acute myeloid leukemia and mul-
tiple myeloma was recently reported.38
We aimed at defining and exploring a new anti-CD44v6 CAR-
CIK adoptive immunotherapy within the challenging setting of
high grade STS. In this model, CIK are engineered with a lentiviral
vector encoding for anti-CD44v6-CAR with a CD28 signaling
domain and HSV-TK inducible suicide switch. We exploited our
experimental platform,10-12,40 based on patient-derived STS cell
cultures, to assess the prevalence and intensity of CD44v6 within a
wide range of STS histotypes. We assessed the efficacy of CAR-
CIK from STS patients, including autologous essays, to provide
reliable preclinical basis for clinical studies in this challenging field.
Results
Generation and characterization of CIK cells redirected
with a CD44v6 CAR
CIK cells were generated from Peripheral Blood Mononuclear
Cells (PBMCs) obtained from 12 patients, with diagnosis of
Soft Tissue Sarcoma (STS), Supplemental table 1. We geneti-
cally engineered CIK to express the CD44v6-specific CAR by
transducing PBMCs at day C3 of culture with the lentiviral vec-
tor LV-CD44v6.CAR28z. Three weeks after transduction we
evaluated the expression of the CD44v6-specific CAR on CIK
(CARC.CIK) by flow cytometry: mean transduction efficiency,
was 68%§3 (mean § SEM) in bulk mature CIK (Fig. 1A), the
rate of the CD3CCD56C subset was comparable between the
CD44v6 CARC/CD3C (Fig. 1B) and the CD44v6 CAR¡/CD3C
fractions (Fig. 1C). The median ex vivo expansion of CARC.
CIK was 37 fold (range 11–645), such value is comparable to
that observed with unmodified CIK (NTD.CIK) used as paired
control (38 fold; range, 9–631, p D ns) (Supplemental table 1),
ruling out any possible detrimental effect caused by lentiviral
transduction or CD44v6 expression in CIK cells. We confirmed
the functionality of the HSV-TK inducible suicide gene
encoded within the LV-CD44v6.CAR28z vector. CARC.CIK
were efficiently ablated by the in vitro exposure to Ganciclovir
(GCV, 10 mM for 72 h) (Supplemental Fig. 1).
The phenotype of mature CARC.CIK was comparable to
that of paired controls with NTD CIK.
The majority of CARC.CIK were CD8C (67%§4, mean §
SEM) with a relevant subset co-expressing CD3 and CD56 mole-
cules (CD3CCD56C) (37%§6, mean § SEM).The median mem-
brane expression of NKG2D receptor was (77%§4, mean §
SEM) and the effector memory (CD62 LCCD45RA¡) was
expectedly the most represented phenotype (40,6%§5, mean §
SEM) (Fig. 1D). A complete phenotype description and compari-
son with NTD.CIK cells is summarized in supplemental table 1.
Expression of CD44v6 by soft tissue sarcomas
To explore the clinical relevance of CD44v6 as a target in STS,
we analyzed its surface expression on 27 STS. Twenty-three
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out of 27 STS cell lines were directly generated from surgical
biopsies obtained at our Center. CD44v6 was expressed at
variable levels in 11 out of 27 (40.7%) STS, with a higher prev-
alence in UPS, liposarcoma and leiomiosarcoma, while lower
prevalence was observed in GIST. The prevalence of CD44v6
expression in different STS histotypes is summarized in
Table 1. Considering the relative fluorescence intensity (RFI)
ratio, the expression of CD44v6 in STS could be classified as
high (RFI >5, 27%), moderate (RFI >2 and <5, 46%) or low
(RFI <2, 27%), Table 2. STS were confirmed to express vari-
able levels of the principal known ligands recognized by the
NKG2D receptor on CIK (MIC A/B, ULBP1, ULBP2/5/6, and
ULBP3). MIC A/B was highly expressed only in two targets
whereas less present or practically absent in the others. Analy-
sis for ULBPs 1 was negligible, whereas ULBPs 2/5/6, and 3
displayed ubiquitous expression. HLA class-I expression was
retained by all STS, Table 2.
Antitumor activity of anti CD44v6 CARCCIK against soft
tissue sarcomas
Activity in vitro
We assessed the killing activity in vitro of CARC.CIK, expanded
from our patients, against 11 different STS. In 4/11 essays we
could reproduce the autologous setting as PBMC and STS tar-
gets from the same patient were available (Supplemental
Fig. 2), CIK from allogeneic patients were used in the 7 remain-
ing cases.
CARC.CIK efficiently killed STS and the killing activity was
significantly higher if compared with unmodified NTD.CIK,
especially at low effector/target ratios (n D 43; p<0.0001
Fig. 2A and supplemental video 1). The STS killing by CARC.
CIK remained intense regardless the variable expression level
(high, intermediate or low) of CD44v6 on tumor membrane,
only a trend toward a better killing was observed against STS
with high (RFI>5) expression of CD44v6 (Fig 2B). The rate of
viable tumor cells continued to progressively decrease up to
72 hours after stopping the experiment and removal of CARC.
CIK (n D 2, supplemental Fig. 3A).
In selected control experiments (n D 4), the addition of anti-
CD44v6 blocking antibody, directed against the same epitope
recognized by the CAR (VFF-18), significantly reduced the kill-
ing ability of CARC.CIK: (P  0.0001, Fig. 2C). The killing
activity was not abrogated but reduced to levels comparable to
unmodified NTD.CIK.
Table 1. CD44v6 expression in STS.
Histotype CD44v6C / Total
Liposarcoma 3/6
Fibrosarcoma 1/1
Leiomiosarcoma 1/2
UPS 4/6
GIST 2/12
Total number 11/27
Figure 1. Phenotype of antiCD44v6 CARC.CIK cells. Mature CIK cells efficiently expressed anti-CD44v6CAR (A). The CD3CCD56C subset of CIK cells was equally distributed
between CARC (B) and CAR¡ (C) cells. CARC.CIK were mostly effector memory (EM / EM RA), followed in order by naive and central memory phenotype (D). The
phenotype was comparable with that of unmodified NTD.CIK (unpaired t test, P > 0.05). Abbreviations: Chimeric Antigen Receptor (CAR); Not Transduced (NTD); Effector
Memory (EM: CD45RA¡/CD62 L-); Effector Memory RA (EM RA: CD45RAC/CD62 L-); Central Memory (CM: CD45RA¡/CD62 LC); NA€IVE: CD45RAC/CD62 LC.
Table 2. Phenotype of STS cell lines.
STS cell line Histotype MIC A/B (%) ULBP1 (%) ULBP2/5/6 (%) ULBP3 (%) HLA (%) CD44v6 (RFI)
HT1080 fibrosarcoma 0 0 80 100 80 9
DMR leiomyosarcoma 0 0 80 100 100 2,8
402.91 Liposarcoma (myxoid) 95 0 98 100 94 2,1
NARAH UPS 20 0 100 90 78 1,2
S5 UPS 3 0 100 75 100 8,5
S1 UPS 13 0 100 90 100 2
S3 UPS 90 0 100 100 100 5,4
S23 Liposarcoma (retroperitoneal dedifferentiated) 0 0 98 5 100 1,7
S26 GIST 0 0 91 6 100 2,7
S25 GIST 10 1 75 9 100 2,4
S24 Liposarcoma (myxoid) 10 5 76 18 87,5 2,5
MEAN % (SEM%) 21,9 (§10,7) 0,5 (§0,4) 90,7 (§3,2) 63,0 (§13) 94,5 (§2,6) 3,6 (§0,8)
Histotype, CIK cell ligands, HLA class I expression and CD44v6 RFI of each CD44v6C STS are reported in the table.
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The addition of anti-NKG2D neutralizing antibody partially
inhibited tumor killing of unmodified NTD.CIK cells but it did
not interfere with the killing activity of CARC.CIK, probably
depending on the intense and homogenous membrane expres-
sion of CD44v6.
We assessed in vitro the killing activity of antiCD44v6
CARC.CIK against monocytes as they were reported to express
CD44v6 with potential risk of monocytopenia. CARC.CIK were
moderately active against monocytes at (E/T 5:1), their killing
activity sensibly decreased at lower E:T ratios (n D 3) (Fig. 2D).
Cytokine production
We explored the production of main Th1 and Th2 type cyto-
kines by CARCCIK upon recognition of CD44v6C STS. A
panel of 11 cytokines (IL-4, IL5, IL-6, IL-10, IL-12, IL-13, IL-
17a, IFN-g, TNF-a, GM-CSF and TGF-b) was determined.
CARC.CIK cells produced significant higher amounts of IL-4
(p < 0.0001) and IFN-g (p < 0.05) compared with unmodified
NTD.CIK (Fig. 3A,D). A positive trend was observed for IL6
(Fig. 3D), while a negative trend was observed for IL5 and
TGF-b (Fig. 3B,E). We did not observe any significant
difference for the other cytokines analyzed. IFN-g was the only
cytokine with a progressive incremental trend (supplemental
Fig. 4).
In vivo activity
We explored the antitumor activity of anti-CD44v6 CARC.CIK
intravenously infused, every 3–4 days, in NOD/SCID mice
bearing subcutaneous STS xenograft generated from a patient-
derived UPS.
After 8 total infusions (dose 4 £ 105) we observed a signifi-
cant delay of tumor growth in mice (n D 6) treated with CARC.
CIK, compared with untreated controls (n D 6, p< 0.0001) or
treated with equivalent doses of paired NTD.CIK cells (n D 6,
p<0.0001) (Fig. 4A). Comparable antitumor activity was
obtained with 1 log-higher dose of CARC.CIK (dose 4 £ 106),
however in this case the differences with NTD.CIK cells were
less evident not reaching statistical significance (Fig. 4A). In
selected cases (n D 5) we could confirm that the therapeutic
effect of CARCCIK was maintained up to 10 days after stopping
Figure 2. Sarcoma killing in vitro by antiCD44v6 CARC.CIK Patient-derived antiCD44v6 CARC.CIK (n D 12) efficiently killed STS (n D 11, autologous targets in 4/11). The
specific killing by CARC.CIK cells was significantly higher, especially at low E/T ratios, than that obtained with unmodified CIK generated from the same patients (A). Killing
values (mean § SEM) from 43 independent essays are reported, results were analyzed by two way ANOVA and Bonferroni post test analysis, statistical significance is
reported as  P  0.05;  P  0.01;  P  0.001;  P  0.0001. The killing activity remained intense regardless the expression level (RFI high, intermediate, low) of
CD44v6 on targets (B). Representative flow-cytometry histograms for each RFI level are reported. The addition of a blocking antibody against CD44v6 reduced the killing
ability of CARC.CIK cells to levels comparable to NTD.CIK. Blocking NKG2D receptor significantly reduced the tumor killing activity of unmodified NTD.CIK but did not
impair CARC.CIK (n D 4) (C). CARC.CIK were moderately capable of killing monocytes at (E/T 5:1), the effect sensibly decreased and ceased at lower E:T ratios (n D 3) (D).
Abbreviations: CAR Chimeric Antigen Receptor; NTD, Not Transduced; STS, Soft Tissue Sarcoma.
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Figure 3. Cytokine production by CARC.CIK. CARC.CIK produced higher amounts of IL4, IFN-g and IL6 compared with NTD.CIK. A trend toward lower production of IL5 and
TGFb was observed. Results are reported as optic density ratio (O.D. ratio) between samples and internal control (according to manufacturer instructions). Unpaired t test
was adopted to compare CARC.CIK with NTD.CIK. Significance is reported as  P  0.05;  P  0.01;  P  0.001;  P  0.0001.
Figure 4. In vivo anti-sarcoma activity of antiCD44v6 CARC.CIK. CARC.CIK were intravenously infused, every 3–4 days (total 8 infusions), in NOD/SCID mice bear-
ing subcutaneous patient-derived UPS xenograft. Two different doses (4 £ 105 and 4 £ 106 per infusion) of CARC.CIK were explored. We observed a significant
delay of tumor growth in mice (n D 6) treated with CARC.CIK cells (4 £ 105), compared with untreated controls (n D 6, p< 0.0001) or treated with equivalent
doses of paired NTD.CIK cells (n D 6, p< 0.0001). A similar antitumor activity was observed with 1 log-higher dose of CARC.CIK (4 £ 106). Arrows indicate CIK
cell infusions. Results were analyzed by Two way Anova and correction for multiple comparisons test using Bonferroni method: Statistical significance is
expressed as  P  0.05;  P  0.01;  P  0.001;  P  0.0001 (A). In selected cases (1 representative mouse per group, n D 5) results were confirmed
by a 3D imaging analysis based of fluorescent glucose uptake (B). Tumor homing of CARC.CIK was confirmed by IHC in explanted tumors by staining with
anti-human CD3 antibody (C). Abbreviations: CAR Chimeric Antigen Receptor; NTD, Not Transduced; NOD SCID mice, Non obese diabetic/severe combined
immunodeficiency mice.
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the infusions (Supplemental Fig. 3B). We did not observe any
relevant toxicity or side effect in mice receiving CARC.CIK at
any dose. At the end of in vivo experiment, the antitumor activ-
ity of CARC.CIK was confirmed by 3D analysis in one repre-
sentative animal per group by assessing the tumor uptake of
fluorescent glucose (probe XenoLight RediJect 2-DeoxyGluco-
sone) (Fig. 4B). The tumor homing of CARCCIK was con-
firmed by IHC in explanted tumors (Fig. 4C), along with the
expression of CD44v6 and NKG2D ligands (Supplemental
Fig. 5).
Discussion
In this study we reported for the first time the intense and safe
anti-sarcoma activity of patient-derived CIK, genetically redir-
ected with a CAR against CD44v6. Results were confirmed in
vitro against multiple histotypes of STS, including autologous
targets, and in an in vivo STS xenograft model.
CAR-T cell have been heralded as a major breakthrough in
the field of adoptive immunotherapy. Impressive clinical results,
admittedly along with important safety warnings, have been
reported against hematologic malignancies, while their potentiali-
ties against solid tumors are still object of intense research. CAR-
CIK cells may be an intriguing therapeutic alternative, especially
in the challenging field of solid tumors including high grade STS.
Promising preclinical data in this direction have been recently
produced against hematologic malignancies, ovarian, nasopha-
ryngeal and EGFR-positive solid tumors.31,32,35,36,41-43
Biologic features of CIK may offer an advantageous experi-
mental platform for CAR-engineered adoptive cell therapy. In
particular the intense ex vivo expansibility, the intrinsic anti-
tumor activity and even the limited persistence in vivo might
be therapeutically exploited. We transduced CIK precursors
in the early days of cultures, exploiting the subsequent mas-
sive expansion to generate relevant rates of CAR-engineered
mature CIK. Lentiviral engineering did not impair the expan-
sion potential or phenotype of CIK. Effector memory
phenotype was the most represented within CAR-CIK, fully
comparable to paired unmodified control CIK. The intense
and cost-effective ex vivo expansibility may have a positive
impact on the feasibility of this approach. Relevant doses of
the final cell product may be obtained and cryopreserved,
assuming the necessity of multiple infusions in consideration
of the limited persistence in vivo of CIK.
This is an important difference with “conventional” CAR-T
lymphocytes as they are mainly employed as single infusion,
with subsequent capacity of in vivo proliferation and long-time
persistence. The phenotype observed in our final cell product
cannot exclude the hypothesis of selected CAR-CIK subsets
capable of longer in vivo persistence, future dedicated studies
with side by side CAR-T cell controls will be required to
address this issue.
From the stand-point of antitumor efficacy, we previously
reported that CIK were capable to kill STS but also showed that
their killing activity sensibly decreased at low effector/target
ratios, with possible limitations in clinical perspective. Such
issue was overcome by CAR-CIK, whose intense killing activity
was maintained at unfavorable, more clinical resembling, effec-
tor/target ratios. From these findings it is possible to imagine a
therapeutic plan with multiple, low but highly effective, doses
of CAR-CIK.
Compared with CAR-T lymphocytes, CAR-CIK already
possess an intrinsic, CAR-independent MHC unrestricted,
tumor-killing ability. We observed that blocking CD44v6 in
tumor targets did not abrogate the killing activity of CAR-CIK,
but it was instead reduced to values comparable with unmodi-
fied CIK. On the other hand, blocking NKG2D did not appar-
ently diminish the efficacy of CAR-CIK, while it significantly
inhibited unmodified CIK. This may be explained by the
intense and homogenous expression of CD44v6 on target cells
used in the essay, effectively eliminated by CAR-CIK. The bi-
specific killing potential of CAR-CIK may limit tumor escape
by clonal selection and be advantageous against tumors with
heterogeneous expression of CD44v6. Similar biologic features,
with intense transduction efficiency and bispecific killing prop-
erties were recently explored with an alternative CAR-strategy
based on clinically applicable NK cell lines such as NK-92.44
Phase I trials demonstrated their safety profile and initial evi-
dence of antitumor activity.45,46 However, an important differ-
ence with the CAR-CIK platform is the allogeneic source of
NK92, potentially triggering host immune-responses that might
limit the repeatability and efficacy of multiple infusions.
Safety of CAR-based approaches is a central issue in the per-
spective of clinical translation. Important and even fatal events
have been reported in some initial clinical studies with CAR-T
lymphocytes against hematologic malignancies. Possible off-
tumor recognition, dose and in vivo persistence are central
aspects that may influence the safety profile of CAR-based
strategies. Important pathogenetic roles may be played by pecu-
liar, life-threatening immunological phenomena related to the
activity of CAR-T cells, like cytokine release syndrome (CRS),
macrophage activation syndrome or tumor lysis syndrome.
47,48We observed that CAR-CIK produce higher IFNg com-
pared with control CIK. This may indicate a stronger Th1 type
response and favor additional innate and adaptive immune
effectors, prompting Ag processing and HLA presentation. On
the other hand the production of IL-4 may, at least in part, sus-
tain a Th2 type polarization ad play a pro-tumoral role.49 We
did not observe an enhanced production of GM-CSF by CAR-
CIK. Along with IFNg, GM-CSF derived from CAR-T was
reported to favorably shape tumor microenvironment through
macrophage activation.50 It is also true that high rates of IFNg
might in turn enhance the expression of PD-L1 at tumor level,
with potential immune-suppressive effects but also providing
speculative rational for synergism with checkpoint inhibitors.
IL6 production also surged upon tumor engagement by
CAR¡CIK, warning about possible risks of cytokine release
syndrome in clinical perspective. Dedicated studies, with
immune-competent models, are warranted to explore a more
complete cytokine panel comparing side by side the CRS risk of
CARCCIK with conventional CAR-T.51
The limited in vivo persistence of CIK, previously discussed
as a potential limitation of the antitumor activity, may be
turned into positive safety implications. Multiple low-dose
infusions of CAR-CIK may be planned to aim at disease con-
trol, but their withdrawal will allow the fast effective control of
potential side effects. Also the theoretical risk of insertional
mutagenesis, associated with the use viral vectors, is addressed
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by the limited lifespan of CAR¡CIK. Furthermore the possible
administration of ganciclovir will provide an additional safety
measure to activate the inducible HSV-TK suicide switch.
The first clinical trial with an anti-CD44v6 mAb (bivatuzu-
mab) directly conjugated with a potent chemotherapeutic agent
(mertansine) raised concerns on potential skin toxicities.52,53
Previous experiments with primary keratinocytes, however,
suggested a low level of CD44v6 expression, and relative resis-
tance to CAR-T cell recognition, as compared to hematological
tumor cells and monocytes.38 Although in the present study we
could not directly study keratinocyte recognition, we confirmed
membrane expression of CD44v6 in monocytes, which were
readily recognized by CAR-CIK, although with lower efficiency
compared with sarcoma cells, suggesting a sufficiently wide
therapeutic window also in the case of STS. Moreover, we pre-
viously reported that CD44v6 is indeed absent on tissue-macro-
phages, ruling out potential bystander damages to healthy
tissues rich in monocyte-derived cells (e.g. macrophages; liver
kupffer cells; microglia). We supported the relevance of the
proposed approach by confirming the expression of CD44v6 in
about 40% of STS screened. The distribution was not homoge-
nous and we found that it was more frequently expressed by
aggressive UPS, Liposarcoma, Fibrosarcoma and Leiomiosar-
coma while less present in GIST (2/12).These findings,
obtained by flow-cytometry, are consistent with a previous
large retrospective immunohistochemistry analysis where
CD44v6 was found in 57% of STS cases and associated with
worse prognosis and higher risk of relapse.1,3 The expression of
CD44v6 across several STS histotypes favorably compares with
that of NY-ESO-1, that is a very relevant target for synovial sar-
comas6,7 but only rarely expressed by other STS.
Our study was limited to STS but the approach described
may be relevant also against other mesenchymal tumors like
osteosarcoma. A recent meta-analysis and systematic review
reported that CD44V6 over-expression is associated with poor
survival and metastasis in osteosarcoma patients.54
Overall our findings support the efficacy of antiCD44v6
CAR-CIK against currently high grade STS and lead basis for
their dedicated exploration in clinical studies. CAR redirection
of CIK may represent, in general, a valuable alternative or inte-
gration to adoptive immunotherapy strategies in the challeng-
ing field of solid tumors.
Materials and methods
Generation and characterization of antiCD44v6 CAR§.CIK
CIK cells were generated from peripheral blood mononuclear
cells (PBMC) of patients with diagnosis of high grade STS.
Patients released informed consent approved by the institu-
tional review board according to the Declaration of Helsinki.
PBMC were isolated by density gradient centrifugation
(Lymphosep, Aurogene) and seeded in cell culture flasks at a
concentration of 2 £ 106 cells/mL in RPMI-1640 medium
(Gibco BRL), consisting of 10% FBS (Sigma), 100 U/mL peni-
cillin, and 100 U/mL streptomycin (Gibco BRL). We added
IFN-g (Miltenyi Biotec; 1,000 U/mL) on day 0 and after
24 hours we activated PBMC using Anti-Biotin MACSiBead
Particles loaded with CD2, CD3, and CD28 antibodies
(Miltenyi Biotec) and human interleukin (IL)-2 IS (Miltenyi
Biotec, 300 U/mL). On day C3, stimulated PBMC were trans-
duced with a lentiviral vector encoding for anti-CD44v6-CAR
containing a CH2CH3 spacer and a CD28 signaling domain
(Casucci et al, Blood 2013), with MOI of 2 by overnight incuba-
tion. Non-transduced CIK were used as paired control. Cells
were expanded over 3 weeks. Fresh medium and IL-2 (300
U/mL) were replaced every 2–3 days as needed and the cell
concentration was maintained at 1.8 £ 106 cells/mL.
Phenotype of CIK was analyzed by standard flow cytometric
assays. The following monoclonal antibodies (mAb) were used:
CD3–fluorescein isothiocyanate (FITC), CD8– phycoerythrin
(PE), CD56–PE, CD314– allophycocyanin (APC, anti-NKG2D),
CD45RA-FITC, CD45RO-PE Cy5, CD62 L-PE (Miltenyi Biotec);
CAR expression was detected with a mAb specific for the IgG1/
CH2CH3 spacer (The Jackson Laboratory).
STS cell lines
Patient-derived soft tissue sarcomas (STS) cell lines were gener-
ated from surgical specimens as previously described (Sangiolo
et al., Can Res. 2014) and cultured in KO DMEM F12 (KO Out
Dulbecco’s Modified Eagle Medium, Gibco BRL) medium with
10% FBS, 25 mmol/L HEPES, 100 U/mL penicillin, and 100 U/
mL streptomycin (Gibco BRL) in a humidified 5% CO2 incuba-
tor at 37C. All tumor samples were derived from patient who
had not previously received a chemotherapy treatment for their
disease.
Patients released informed consent approved by the institu-
tional review board according to the Declaration of Helsinki.
HT1080 cell line [American Type Culture Collection
(ATCC)] used in this study was authenticated by genotype
analysis with Cell_ID system (Promega) and comparing their
profile with those published on the DMSZ database. We
received DMR,55 402.9156 and NARA-H55 cell lines as kind gifts
from Spessotto P., Kawamoto T. and Akisue T., Aman P.,
respectively. All STS cell lines were grown in RPMI-1640 sup-
plemented with 10% FBS (Sigma-Aldrich), 25 mmol/L HEPES,
100 U/mL penicillin, and 100 U/mL streptomycin (Gibco BRL)
in a humidified 5% CO2 incubator at 37C. Cell aliquots were
stained with fluorescein isothiocyanate, PE, PE–Cyanin 7
(PC7), or APC-conjugated mouse mAbs against HLA-ABC
(anti-HLA-ABC-FITC, BD Pharmingen) and CIK target anti-
gens (anti-MIC A/B, BD Pharmingen; anti-ULBPs, R&D Sys-
tem, Space Import Export). Cells were stained for CD44v6
(CD44v6-PE e-Bioscience) and relative fluorescence intensity
(RFI) of CD44v6 was calculated as follows: mean fluorescence
intensity after mAb staining/mean fluorescence intensity after
isotype-control staining.
Sarcoma killing activity of antiCD44v6 CAR§.CIK
The tumor-killing abilities of patient-derived antiCD44v6 CARC.
CIK and unmodified NTD.CIK were assessed in vitro against STS
cell lines either by flow-cytometry or bioluminescent cell viability
essay. In the first case target cells were stained with the vital
dye CFSE (5,6-carboxyfluorescein diacetate succinimidyl ester;
Molecular Probes) in accordance with the manufacturer’s proto-
col. The immune-mediated killing was determined evaluating cell
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viability by flow cytometry (Cyan ADP, Beckman Coulter s.r.l.),
after 72-hour incubation with expanded antiCD44v6 CARC.CIK
or unmodified NTD.CIK cells at various effectors/target ratios
(10:1, 5:1, 2.5:1, 1:1, 1:2 and 1:4 for 72 hours in culture medium
with 300 U/mL IL2 at 37C, 5% CO2), according to the formula:
experimental ¡ spontaneous mortality/(100 ¡ spontaneous
mortality) £ 100. Cell viability essays were performed at the
same effector/target ration with CellTiter-Glo Luminescent
Cell Viability Assay (Promega).
In selected blocking experiments, we pre-incubated CIK with
20 mg/mL of neutralizing NKG2D-specific mAb (Clone #149810,
R&D Systems) or pre-incubated STS cells with 10 mg/mL of neu-
tralizing CD44v6-specific mAb (bivatuzumab) that were main-
tained during the cytotoxicity assay against targets. Suicide gene
functionality was analyzed after exposing antiCD44v6 CARC.
CIK for three days to ganciclovir 10 mM (Sigma Aldrich).
In selected assays (n D 2) at the end of experiment, the
recovery of sarcoma cells was evaluated analyzing their growth
rate 72 hours after the removal of CARC.CIK.
Analysis of cytokine secretion
AntiCD44v6 CARC.CIK and unmodified NTD.CIK were incu-
bated with STS targets (E/T 1:1) for 72 h in CIK-culture
medium described above. Thereafter, supernatants from
the co-cultures and from wells with CIK or tumor cells alone
were collected. Cytokine production was analyzed with multi-
analyte EliSArray Kit (Human Th1 / Th2 / Th17 Cytokines
Multi-Analyte ELISArray Kit, Qiagen). IL2 was excluded by the
final analysis as already present in the CIK culture medium.
In vivo activity of patient-derived antiCD44v6 CAR§.CIK
Experiments were approved by internal review board. NOD/
SCID (Charles River) female mice were subcutaneously injected
with 3 £ 106 primary cells of patient-derived pleomorphic sar-
coma, resuspended in sterile PBS and BD Matrigel Basement
Membrane Matrix (Becton Dickinson) 1:1. When tumors were
approximatively 200 mm3, mice were infused twice-weekly
with 4 £ 106 or 4 £ 105 mature antiCD44v6 CARC.CIK or
NTD.CIK cells resuspended in PBS (200 mL), for a total of 8
infusions. Mice injected with PBS only were used as control.
Tumor growth was weekly monitored with a caliper and
volume calculated according to the formula: V D 4/3 £ p £
(a/2)2£ (b/2), where a is the length and b is the width diameter
of the tumor.. Experiment ended and animals were euthanized
2 weeks after the last treatment or when tumor reached 2 cm in
the main diameter.
Imaging by fluorescent glucose in vivo
At the end of in vivo treatments, a representative animal per
cohort was intravenously infused with the fluorescent probe
XenoLight RediJect 2-DeoxyGlucosone (DG)-750 (Perki-
nElmer) (5 nmol/mouse). Images based on the uptake of fluo-
rescent glucose by tumors were acquired with Living Image 
Software and the IVIS  Spectrum CT (Caliper Corporation,
PerkinElmer Company).
Immunohistochemistry (IHC)
In selected cases (2 mice per group) we explored by IHC the
presence of CARCCIK in the explanted tumors along with the
expression of NKG2D ligands (MIC A/B; ULBPs 2,5,6) and
CD44v6.
Sections from formalin fixed, paraffin-embedded samples
were cut into 3-mm thick sections. The tissue slides were
treated according to standard immunohistochemistry proce-
dures. In short, the slides were permeabilized in 0.1% Triton
X-100 and 0.3% Tween 20 (Sigma-Aldrich) in TBS, treated
for 30 min with 1% hydrogen peroxide to quench endoge-
nous peroxidases. The slides were incubated with individual
primary antibodies overnight at 4C inside a moist chamber.
After rinsing in PBS, a secondary antibody was added. Sec-
ondary HRP-conjugate antibodies (EnVision; DakoCytoma-
tion) were used for immunohistochemistry and the reaction
was visualized with DAB chromogen (DakoCytomation Liq-
uid DAB Substrate Chromogen System, Dako). The tissues
were counterstained with Mayer hematoxylin (Bio-Optica),
mounted on glass slides and visualized with a BX-60 micro-
scope (Olympus) equipped with a color Qicam Fast 1394-
digital CCD camera (12 bit; QImaging). The tissues were
stained with the following primary antibodies: anti–CD3
(DAKO); anti-MIC A/B (clone #159207, R&D SYSTEM,
BIOTECHNE BRAND); anti-ULBP 2/5/6 (R&D SYSTEM,
BIOTECHNE BRAND); anti-CD44v6 (clone #SP37, Acris,
an OriGene Company).
Statistical analysis
Descriptive data were calculated and reported as mean or
median values, calculated as appropriate.
Phenotype and cytokine production between CARCCIK
and NTD CIK were compared by 2-tailed Student t tests.
Comparison of antitumor activity among groups was calcu-
lated by two-way analysis of variance (ANOVA) and multi-
ple comparison post-test analysis by Bonferroni method.
Differences with a P value < 0.05 were considered statisti-
cally significant.57
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